This morning, ATAI Life Sciences (Nasdaq: ATAI) experienced a shocking drop of nearly 40% in its stock price, plummeting to an all-time low since the company’s June 2021 Initial Public Offering. The cause? A failed lead asset from its majority-owned Perception Neuroscience unit.
Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Cathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance, is that a good thing?
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.